Inhalon BioPharma founded by Sam Lai, Ph.D.

Received $500,000 from The Thiel Foundation through Breakout Labs

Appointed John Whelan as Chief Executive Officer

Raised 3.1M in Series Seed led by Life Science Angels

Awarded $7 Million grant from U.S. Army Medical Research & Development Command (USAMRDC) to Study IN-006 an Inhaled "Muco-trapping" Antibody for the Treatment of COVID-19

Appointed Jeff Hutchins, Ph.D. as Chief Development Officer

Dosed First Patient in Phase 1 Study of Inhaled IN-006

Completed Phase 1 study of Inhaled IN-006

Raised $5M in Series A led by JSR Life Sciences and Life Science Angels

Awarded $2M Grant from National Institutes of Health (NIH) for IND enabling development on IN-002, potential treatment for respiratory syncytial virus (RSV)

Released data for IN-006-01 at https://www.medrxiv.org/content/10.1101/2022.08.17.22278748v1

Awarded 1.7M grant from the North Carolina Collaboratory at University of North Carolina at Chapel Hill to Develop IN-007 An Inhaled ACE2-Targeting Therapeutic Prototype

Dosed First Patient in Phase 1b Study of Inhaled IN-006 (Study IN-006-02)

Awarded $1M from NIH to support IN-002 for RSV

Awarded $6M grant from Medical Technology Enterprise Consortium (MTEC) to Study IN-007